Cheryl Ard
Adult Health · Statesboro, GANPI 1780938647
Payments from drug & device makers
Across 160 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$932
- Novo Nordisk$361
- GSK$224
- Pfizer$213
- Amgen$113
- Abbott$112
- plus $877 from 23 others
What the payments were for
- Food & beverage$2,832100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 52 | $932 |
| Novo Nordisk | 18 | $361 |
| GSK | 13 | $224 |
| Pfizer | 12 | $213 |
| Amgen | 7 | $113 |
| Abbott | 6 | $112 |
| E.r. Squibb & Sons, L.L.C. | 5 | $92 |
| Halozyme Inc | 3 | $84 |
| Merck | 5 | $77 |
| Lilly USA, LLC | 4 | $73 |
| Boehringer Ingelheim | 5 | $67 |
| AstraZeneca | 4 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Athena Bioscience, LLC | 2 | $37 |
| Johnson & Johnson | 2 | $37 |
| Inogen, Inc. | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 2 | $28 |
| Dexcom, Inc. | 2 | $28 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| Linus Health, Inc. | 1 | $14 |
| Upsher-smith Laboratories LLC | 1 | $12 |
How this compares
$2,832 in reported general payments places this provider in the 80th percentile of 577 adult health providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $49,345 |
| FarxigaDapagliflozin Propanediol | 22 | $19,580 |
| XareltoRivaroxaban | 11 | $17,463 |
| MounjaroTirzepatide | 11 | $14,143 |
| MyrbetriqMirabegron | 18 | $13,211 |
| TrulicityDulaglutide | 13 | $12,647 |
| JardianceEmpagliflozin | 14 | $11,907 |
| EntrestoSacubitril/Valsartan | 11 | $7,822 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $2,953 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $2,221 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,122 |
| Gabapentin | 109 | $1,417 |
| Aripiprazole | 14 | $1,316 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,097 |
| Pravastatin Sodium | 40 | $765 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $361 | $49,34536 claims |
| Lilly USA, LLCMounjaro, Trulicity | $73 | $26,79024 claims |
| AstraZenecaFarxiga, Symbicort | $64 | $22,53335 claims |
| Johnson & JohnsonXarelto | $37 | $17,46311 claims |
| Boehringer IngelheimJardiance | $67 | $11,90714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 577 adult health providers in Georgia.
Other adult health in Statesboro
- Tina HathawayStatesboro$5K
- Patricia KeeganAtlanta$224K
- Diane WirthAtlanta$132K
- Barbara WeberAtlanta$74K
- Terry HackworthAtlanta$49K
- Jenny DicksonCumming$39K
- Rachel NejemLawrenceville$31K
- Melissa BaughcumAthens$23K
- Kristine AdamsMarietta$21K
- Jenina LagascaAtlanta$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.